Mode
Text Size
Log in / Sign up

Radiomics features on MRI discriminate sellar LCH from tumor marker-negative GCTs with an AUC of 0.81.

Radiomics features on MRI discriminate sellar LCH from tumor marker-negative GCTs with an AUC of 0.8…
Photo by Craig Cameron / Unsplash
Key Takeaway
Note that radiomics features on MRI may help distinguish sellar LCH from GCTs, but data are limited.

This retrospective cohort study included 93 patients diagnosed pathologically or by therapeutic diagnosis with sellar region tumors. The primary objective was to discriminate between tumor marker-negative sellar germ cell tumors (GCTs) and Langerhans cell histiocytosis (LCH). The intervention involved extracting radiomics features from multiparametric MRI sequences, specifically T1WI and T2WI. These features were combined with clinical features and imaging semantic features using a random forest (RF) classifier.

The main result showed an area under the curve (AUC) of 0.81 for the combined model. Specific absolute numbers regarding sensitivity or specificity were not reported, nor were p-values or confidence intervals provided. Safety and tolerability data, including adverse events or discontinuations, were not reported. The study was conducted at a single institution, and follow-up duration was not reported.

Key limitations include the single-institution setting and the lack of reported statistical significance or safety profiles. As this is an observational study, causal language is inappropriate. The practice relevance is uncertain given the incomplete reporting of secondary outcomes and safety data.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundDifferentiating sellar region germ cell tumors (GCTs) from Langerhans cell histiocytosis (LCH) is challenging due to highly similar MRI features, especially in tumor marker-negative patients. In this study, we aimed to develop and validate a radiomics model to distinguish tumor marker-negative sellar GCTs from LCH.MethodsThis retrospective study enrolled a total of 93 patients diagnosed pathologically or by therapeutic diagnosis at our single institution between April 2012 and April 2024, including 40 cases of LCH and 53 cases of GCTs. Radiomics features extracted from multiparametric MRI, including T1-weighted imaging (T1WI) and T2-weighted imaging (T2WI). We manually segmented the regions of interests (ROIs) of tumors. Feature selection was subsequently performed using LASSO regression with five-fold cross-validation. We have chosen three machine learning classifiers-Support Vector Machine (SVM), Random Forest (RF), and Logistic Regression (LR) to construct models based on the 7 features which were retained. Additionally, by integrating clinically significant features and imaging semantic features, classification models based on radiomics features, imaging semantic features, and clinical features were developed separately. There are 7 models in total. Furthermore, combined prediction models were constructed based on different fusion feature sets, respectively. The performance of the diagnostic model was evaluated using the receiver operating characteristic (ROC) curve. The mean area under the curve (AUC), sensitivity, specificity, accuracy, and F1-score were calculated for both the development set and the test set. Differences in AUC between models were assessed using DeLong's test, and the resulting P-values were adjusted using the Bonferroni false discovery rate (FDR) correction method. Code available upon request.ResultsThe best diagnostic performance was achieved by the combined model of radiomics with clinical features and imaging semantic features using the RF classifier, with an AUC value of 0.81. A statistically significant difference (p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.